Genflow Biosciences PLC – Company to present its Gene Therapy at Animal Longevity Summit 2026

Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (“Genflow” or “the Company”) an emerging leader in the field of longevity research, today announces that it has been invited to present data from its SLAB (Sarcopenia and Longevity in Aged Beagles) clinical study at the Animal Longevity Summit (“ALOS”), taking place in Toronto, Canada, on 1-2 October 2026.

ALOS is the first conference dedicated exclusively to animal longevity and is expected to bring together leading researchers, veterinary scientists, biotechnology companies, and investors focused on extending healthy lifespan in companion animals. Confirmed speakers include Dr. Matt Kaeberlein, Dr. Vera Gorbunova, Dr. Aubrey de Grey, Liz Parrish, Dr. Noah Davidsohn, and Dr. Varun Dwaraka.

Further details regarding the presentation schedule will be announced by the conference organisers.

Dr. Eric Leire, Chief Executive Officer of Genflow, commented: “We are pleased to have been invited to present our SLAB study findings at the Animal Longevity Summit, a leading forum dedicated to advancing the science of healthy aging in companion animals. The study represents an important step in evaluating the potential of our proprietary centenarian SIRT6 gene therapy approach in a real-world aging model. We look forward to sharing the data with researchers, veterinarians, industry participants and investors focused on the emerging longevity sector.”

About the SLAB Study

The SLAB (Sarcopenia and Longevity in Aged Beagles) study is evaluating the safety and biological activity of Genflow’s proprietary SIRT6 centenarian gene therapy in aged beagles. The study began in March 2025 and ends in June 2026.